Search
Pipemidic acid
go.drugbank.com/drugs/DB13823InvestigationalPipemidic acid is a quinolone antibacterial agent with activity against various gram-positive and gram-negative bacteria.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPiperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalPiperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China . Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became availab...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsTenofovir
go.drugbank.com/drugs/DB14126InvestigationalTenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog....
Categories: P-glycoprotein substratesAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS in...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesZavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalZavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways. CGRP receptors...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLeniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigationalLeniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesTebipenem pivoxil
go.drugbank.com/drugs/DB16840ApprovedTebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis. Carbapenems are the standard treatme...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersVepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigationalVepdegestrant is a potent, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) small molecule estrogen receptor (ER) degrader. It was identified through a targeted medicinal chemistry optimization campaign to act as...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InhibitorsCamizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigationalCamizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally advanced or metastatic breast...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTelmapitant
go.drugbank.com/drugs/DB20768ExperimentalThe usage of the INN stem '-pitant' in the name indicates that Telmapitant is a neurokinin NK1 (substance P) receptor antagonist. Telmapitant has a monoisotopic molecular weight of 515.16 Da.